Rodney E Wegner1, Stephen Abel2, Randy S D'Amico3, Gautam U Mehta4, Jason Sheehan5. 1. Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, USA. rodney.wegner@ahn.org. 2. Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, USA. 3. Department of Neurosurgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra, New York, USA. 4. Division of Neurosurgery, House Ear Institute, Los Angeles, USA. 5. Department of Neurosurgery, University of Virginia School of Medicine, Charlottesville, USA.
Abstract
BACKGROUND: The role of immunotherapy for metastatic melanoma has expanded over the past decade triggering questions regarding the combination and timing of immunotherapy and radiation for brain metastases. We used the National Cancer Database (NCDB) to see if the time from radiation to immunotherapy in patients with melanoma brain metastases had an impact on survival. METHODS: We queried the NCDB from 2010 to 2015 for patients with melanoma brain metastases treated with immunotherapy and stereotactic radiosurgery (SRS). Receiver operator characteristic (ROC) curve analysis was done to determine a timepoint associated with outcome. Cox regression was used to identify predictors of survival. Propensity matching was done to account for indication bias. RESULTS: We identified 247 patients meeting the above criteria. The median patient age was 62 years (27-90) and the vast majority were Caucasian (99%). The median SRS dose was 22 Gy (18-24 Gy).The median time to SRS was 39 days (0-344) and the median time to immunotherapy was 56 days (6-454). The ROC analysis revealed 8 days from SRS to immunotherapy as associated with outcome. Fifty-six patients had immunotherapy prior to SRS, 30 patients had immunotherapy within 0-7 days of SRS, and the remaining 161 had immunotherapy greater than 7 days from SRS. Three year survival rates were 21%, 55%, and 35% for those timeframes, respectively (p = 0.0153). Propensity matching of the 0-7 day and > 7 day groups yielded 28 pairs and Kaplan Meier analysis showed 3 year overall survival of 55% and 35%, in favor of immunotherapy within 7 days of SRS (p = 0.0357). Multivariable Cox regression identified lack of extracranial disease, more recent year of treatment, and time from SRS to immunotherapy of 0-7 days as predictors of improved survival. CONCLUSIONS: Immunotherapy within 7 days of SRS shows a possible association with improve outcomes in patients with brain metastases from melanoma.
BACKGROUND: The role of immunotherapy for metastatic melanoma has expanded over the past decade triggering questions regarding the combination and timing of immunotherapy and radiation for brain metastases. We used the National Cancer Database (NCDB) to see if the time from radiation to immunotherapy in patients with melanoma brain metastases had an impact on survival. METHODS: We queried the NCDB from 2010 to 2015 for patients with melanoma brain metastases treated with immunotherapy and stereotactic radiosurgery (SRS). Receiver operator characteristic (ROC) curve analysis was done to determine a timepoint associated with outcome. Cox regression was used to identify predictors of survival. Propensity matching was done to account for indication bias. RESULTS: We identified 247 patients meeting the above criteria. The median patient age was 62 years (27-90) and the vast majority were Caucasian (99%). The median SRS dose was 22 Gy (18-24 Gy).The median time to SRS was 39 days (0-344) and the median time to immunotherapy was 56 days (6-454). The ROC analysis revealed 8 days from SRS to immunotherapy as associated with outcome. Fifty-six patients had immunotherapy prior to SRS, 30 patients had immunotherapy within 0-7 days of SRS, and the remaining 161 had immunotherapy greater than 7 days from SRS. Three year survival rates were 21%, 55%, and 35% for those timeframes, respectively (p = 0.0153). Propensity matching of the 0-7 day and > 7 day groups yielded 28 pairs and Kaplan Meier analysis showed 3 year overall survival of 55% and 35%, in favor of immunotherapy within 7 days of SRS (p = 0.0357). Multivariable Cox regression identified lack of extracranial disease, more recent year of treatment, and time from SRS to immunotherapy of 0-7 days as predictors of improved survival. CONCLUSIONS: Immunotherapy within 7 days of SRS shows a possible association with improve outcomes in patients with brain metastases from melanoma.
Authors: Angela M Hong; Gerald B Fogarty; Kari Dolven-Jacobsen; Bryan H Burmeister; Serigne N Lo; Lauren E Haydu; Janette L Vardy; Anna K Nowak; Haryana M Dhillon; Tasnia Ahmed; Brindha Shivalingam; Georgina V Long; Alexander M Menzies; George Hruby; Katharine J Drummond; Catherine Mandel; Mark R Middleton; Claudius H Reisse; Elizabeth J Paton; Victoria Steel; Narelle C Williams; Richard A Scolyer; Rachael L Morton; John F Thompson Journal: J Clin Oncol Date: 2019-09-25 Impact factor: 44.544
Authors: Chad Tang; Xiaohong Wang; Hendrick Soh; Steven Seyedin; Maria Angelica Cortez; Sunil Krishnan; Erminia Massarelli; David Hong; Aung Naing; Adi Diab; Daniel Gomez; Huiping Ye; John Heymach; Ristuko Komaki; James P Allison; Padmanee Sharma; James W Welsh Journal: Cancer Immunol Res Date: 2014-09 Impact factor: 11.151
Authors: Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: JAMA Date: 2016-07-26 Impact factor: 56.272
Authors: Prashant Gabani; Benjamin W Fischer-Valuck; Tanner M Johanns; Leonel F Hernandez-Aya; Jesse W Keller; Keith M Rich; Albert H Kim; Gavin P Dunn; Clifford G Robinson; Michael R Chicoine; Jiayi Huang; Christopher D Abraham Journal: Radiother Oncol Date: 2018-06-27 Impact factor: 6.280
Authors: Claire M Lanier; Ryan Hughes; Tamjeed Ahmed; Michael LeCompte; Adrianna H Masters; William J Petty; Jimmy Ruiz; Pierre Triozzi; Jing Su; Stacy O'Neill; Kuonosuke Watabe; Christina K Cramer; Adrian W Laxton; Stephen B Tatter; Ge Wang; Christopher Whitlow; Michael D Chan Journal: Neurooncol Pract Date: 2019-02-05
Authors: Sebastian Rubino; Daniel E Oliver; Nam D Tran; Michael A Vogelbaum; Peter A Forsyth; Hsiang-Hsuan Michael Yu; Kamran Ahmed; Arnold B Etame Journal: Front Oncol Date: 2022-03-02 Impact factor: 6.244